Cargando…

A comparative study of esketamine-dexmedetomidine and sufentanil-dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA): a randomized double-blind clinical trial

OBJECTIVE: To observe and evaluate the effectiveness and safety of Esketamine or Sufentanil combined with Dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA) to provide a clinical basis for the optimization of sedation and analgesia in lung tumor PRFA...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Zhonglan, Li, Shuxin, Zhou, Yun, Lu, Xinlei, Yang, Bin, Yu, Zhengwei, Cheng, Yuan, Sun, Jianliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486108/
https://www.ncbi.nlm.nih.gov/pubmed/37684574
http://dx.doi.org/10.1186/s12871-023-02266-y
_version_ 1785102934504112128
author Lin, Zhonglan
Li, Shuxin
Zhou, Yun
Lu, Xinlei
Yang, Bin
Yu, Zhengwei
Cheng, Yuan
Sun, Jianliang
author_facet Lin, Zhonglan
Li, Shuxin
Zhou, Yun
Lu, Xinlei
Yang, Bin
Yu, Zhengwei
Cheng, Yuan
Sun, Jianliang
author_sort Lin, Zhonglan
collection PubMed
description OBJECTIVE: To observe and evaluate the effectiveness and safety of Esketamine or Sufentanil combined with Dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA) to provide a clinical basis for the optimization of sedation and analgesia in lung tumor PRFA protocols outside the operating room. METHODS: In this trial, 44 patients aged 37 to 84 undergoing lung tumor PRFA were enrolled and assigned to Group E (n = 22, Esketamine 0.2 mg/kg) or Group S (n = 22,Sufentanil 0.1 μg/kg ). Dexmedetomidine was infused intravenously as a sedative in both groups. The modified observer’s assessment of alertness and sedation scale (MOAAS), physical movement pain scale, intraoperative vital signs, anesthesia recovery time, radiologist and patient satisfaction rates, incidence of respiratory depression, and incidence of postoperative nausea and vomiting were recorded. RESULTS: Although there was no significant difference in the physical movement pain scale, blood oxygen saturation or incidence of perioperative adverse events between the two groups during ablation, the MOAAS, mean arterial pressure (MAP) and heart rate (HR) were higher in Group E than in Group S. The anesthesia recovery time was shorter in Group E than in Group S, and radiologist satisfaction was better in Group E than in Group S, but there was no significant difference between the two groups in terms of patient satisfaction. CONCLUSION: Esketamine or Sufentanil combined with Dexmedetomidine is safe for lung tumor PRFA. However, in elderly patients with multiple underlying diseases, low-dose Esketamine combined with Dexmedetomidine has fewer hemodynamic effects on patients, milder respiratory depression, shorter recovery time, and better radiologist satisfaction because of its better controllability of sedation depth. TRIAL REGISTRATION: Chinese Clinical Trial Registry (Registration number#ChiCTR ChiCTR21000500 21); Date of Registration: 16/08/2021
format Online
Article
Text
id pubmed-10486108
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104861082023-09-09 A comparative study of esketamine-dexmedetomidine and sufentanil-dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA): a randomized double-blind clinical trial Lin, Zhonglan Li, Shuxin Zhou, Yun Lu, Xinlei Yang, Bin Yu, Zhengwei Cheng, Yuan Sun, Jianliang BMC Anesthesiol Research OBJECTIVE: To observe and evaluate the effectiveness and safety of Esketamine or Sufentanil combined with Dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA) to provide a clinical basis for the optimization of sedation and analgesia in lung tumor PRFA protocols outside the operating room. METHODS: In this trial, 44 patients aged 37 to 84 undergoing lung tumor PRFA were enrolled and assigned to Group E (n = 22, Esketamine 0.2 mg/kg) or Group S (n = 22,Sufentanil 0.1 μg/kg ). Dexmedetomidine was infused intravenously as a sedative in both groups. The modified observer’s assessment of alertness and sedation scale (MOAAS), physical movement pain scale, intraoperative vital signs, anesthesia recovery time, radiologist and patient satisfaction rates, incidence of respiratory depression, and incidence of postoperative nausea and vomiting were recorded. RESULTS: Although there was no significant difference in the physical movement pain scale, blood oxygen saturation or incidence of perioperative adverse events between the two groups during ablation, the MOAAS, mean arterial pressure (MAP) and heart rate (HR) were higher in Group E than in Group S. The anesthesia recovery time was shorter in Group E than in Group S, and radiologist satisfaction was better in Group E than in Group S, but there was no significant difference between the two groups in terms of patient satisfaction. CONCLUSION: Esketamine or Sufentanil combined with Dexmedetomidine is safe for lung tumor PRFA. However, in elderly patients with multiple underlying diseases, low-dose Esketamine combined with Dexmedetomidine has fewer hemodynamic effects on patients, milder respiratory depression, shorter recovery time, and better radiologist satisfaction because of its better controllability of sedation depth. TRIAL REGISTRATION: Chinese Clinical Trial Registry (Registration number#ChiCTR ChiCTR21000500 21); Date of Registration: 16/08/2021 BioMed Central 2023-09-08 /pmc/articles/PMC10486108/ /pubmed/37684574 http://dx.doi.org/10.1186/s12871-023-02266-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lin, Zhonglan
Li, Shuxin
Zhou, Yun
Lu, Xinlei
Yang, Bin
Yu, Zhengwei
Cheng, Yuan
Sun, Jianliang
A comparative study of esketamine-dexmedetomidine and sufentanil-dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA): a randomized double-blind clinical trial
title A comparative study of esketamine-dexmedetomidine and sufentanil-dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA): a randomized double-blind clinical trial
title_full A comparative study of esketamine-dexmedetomidine and sufentanil-dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA): a randomized double-blind clinical trial
title_fullStr A comparative study of esketamine-dexmedetomidine and sufentanil-dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA): a randomized double-blind clinical trial
title_full_unstemmed A comparative study of esketamine-dexmedetomidine and sufentanil-dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA): a randomized double-blind clinical trial
title_short A comparative study of esketamine-dexmedetomidine and sufentanil-dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA): a randomized double-blind clinical trial
title_sort comparative study of esketamine-dexmedetomidine and sufentanil-dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (prfa): a randomized double-blind clinical trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486108/
https://www.ncbi.nlm.nih.gov/pubmed/37684574
http://dx.doi.org/10.1186/s12871-023-02266-y
work_keys_str_mv AT linzhonglan acomparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT lishuxin acomparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT zhouyun acomparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT luxinlei acomparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT yangbin acomparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT yuzhengwei acomparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT chengyuan acomparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT sunjianliang acomparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT linzhonglan comparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT lishuxin comparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT zhouyun comparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT luxinlei comparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT yangbin comparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT yuzhengwei comparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT chengyuan comparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial
AT sunjianliang comparativestudyofesketaminedexmedetomidineandsufentanildexmedetomidineforsedationandanalgesiainlungtumorpercutaneousradiofrequencyablationprfaarandomizeddoubleblindclinicaltrial